IDEX Reports Second Quarter Results

Highlights

(All comparisons are against the prior year period unless otherwise noted)

• Record sales of $921 million increased 6% on a reported basis and 5% organically
• Reported diluted EPS of $1.93 increased 11% and record adjusted diluted EPS of $2.32 increased 12%
• Record orders of over $1 billion increased 29% on a reported basis and 28% organically
• Returned capital to shareholders via $77 million of share repurchases and $54 million of dividends
• Raising full year 2026 organic growth and adjusted EPS guidance ranges

NORTHBROOK, Ill.--(BUSINESS WIRE)-- IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended June 30, 2026.

“We are very pleased to see continued results momentum as our IDEX teams drove another quarter of strong sales and earnings growth. Orders of over $1 billion in the quarter were a record as we continue to see elevated demand across the advantaged markets where we’ve focused our investments and capabilities,” said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.

“Our teams executed exceptionally well, as flow-through on strong volume drove earnings above our expectations, demonstrating the benefits of the work already completed to strengthen the quality of our businesses. We continue to advance 8020 initiatives to both fuel higher growth and unlock further margin expansion opportunities across IDEX.”

“We are increasing our full-year financial guidance expectations due to our strong performance year-to-date and improved visibility in the second half of our fiscal year.”

Outlook⁽¹⁾

• Full year organic sales projected to increase 5% to 6% over the prior year, up from previous guidance of 3% to 4%
• Full year adjusted diluted EPS of $8.70 to $8.85, up approximately 10% year-over-year at midpoint, up from previous guidance of $8.35 to $8.55
• Third quarter 2026 organic sales projected to increase 5% to 7% from the prior year period
• Third quarter 2026 adjusted diluted EPS of $2.20 to $2.25

⁽¹⁾ The Company does not reconcile its forward-looking non-GAAP measures to the most directly comparable U.S. GAAP financial measure because the timing and magnitude of certain items, including future foreign exchange impacts, acquisitions, divestitures, restructuring costs, impairments, tax impacts, and other special items, cannot be reasonably estimated at this time without unreasonable effort. The unavailable information could have a significant impact on GAAP results.